Jennifer Emmert
Interventional Pain Medicine · Lafayette, INNPI 1659323046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 34.9% of the total. That places this record below the midpoint for interventional pain medicine clinicians in IN, where the typical reported total is $4,157.
Across 254 payments — averaging $12.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Arbor Pharmaceuticals, Inc.$210
- Boston Scientific$199
- Pfizer$199
- Vertos Medical, Inc.$178
- Almatica Pharma LLC$168
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,26399%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 99 | $1,150 |
| Arbor Pharmaceuticals, Inc. | 11 | $210 |
| Boston Scientific | 19 | $199 |
| Pfizer | 23 | $199 |
| Vertos Medical, Inc. | 3 | $178 |
| Almatica Pharma LLC | 36 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $140 |
| Biohaven Pharmaceuticals, Inc. | 7 | $133 |
| Scilex Pharmaceuticals Inc. | 7 | $128 |
| Tersera Therapeutics LLC | 4 | $116 |
| Azurity Pharmaceuticals, Inc. | 4 | $99 |
| Amgen | 2 | $57 |
| Pacira Therapeutics, Inc. | 3 | $47 |
| MML US, Inc. | 4 | $45 |
| Gilead | 1 | $42 |
| Biodelivery Sciences International, Inc. | 3 | $42 |
| Collegium Pharmaceutical, Inc. | 3 | $42 |
| Abbott | 2 | $35 |
| Lilly USA, LLC | 2 | $31 |
| Virtus Pharmaceuticals LLC | 1 | $23 |
| Painteq LLC | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Valinor Pharma, LLC | 1 | $20 |
| MDD US Operations, LLC | 1 | $19 |
| Biotronik NRO, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $18 |
| Masimo Corporation | 1 | $17 |
| Si-bone, Inc. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Tonix Medicines, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- mild Device Kit$125
How this compares
$3,294 in reported general payments places this provider in the 40th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 57 | $42,121 |
| Nurtec OdtRimegepant Sulfate | 21 | $30,464 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 995 | $23,194 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 165 | $22,608 |
| UbrelvyUbrogepant | 11 | $13,974 |
| OxycontinOxycodone Hcl | 11 | $9,674 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 358 | $9,145 |
| Pregabalin | 209 | $7,178 |
| Lidocaine | 30 | $7,066 |
| Gabapentin | 370 | $6,413 |
| MovantikNaloxegol Oxalate | 13 | $5,440 |
| Buprenorphine | 17 | $4,785 |
| Oxycodone Hcl | 126 | $2,292 |
| Tizanidine Hcl | 162 | $2,184 |
| Celecoxib | 31 | $1,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $42 | $42,12157 claims |
| PfizerNurtec Odt | $199 | $30,46421 claims |
| AbbVieUbrelvy | $1,150 | $13,97411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Lafayette
- Joseph RutledgeLafayette$96K
- Mohamad SebaiLafayette$10K
- Kelly GrottLafayette$2K
- Shelle SchumacherLafayette$735
- Joshua WellingtonCarmel$315K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.